Immuno-Biological Laboratories Co., Ltd. and ADx NeuroSciences N.V. sign a Collaborative Research and Development Agreement in the field of Alzheimer's disease

We are pleased to announce that Immuno-Biological Laboratories Co., Ltd. (“IBL”) has decided to enter a collaborative research and development agreement with ADx NeuroSciences N.V. (“ADx”). The agreement will be mutually signed by both parties at the signing ceremony of Belgian Royal Crown Prince Mission held in Okura Hotel in Tokyo, Japan on 11th June 2012.

IBL has a broad range of research use only (RUO) product portfolio in Alzheimer disease and has several unique antibodies and ELISA kits which enable to specifically detect a certain protein called “Amyloid Beta” which is cleaved from the Amyloid precursor protein. Amyloid Beta is most commonly known in association with Alzheimer’s disease.

Core members of ADx have extensive experience and knowledge of R&D work and strategies for developing and commercializing novel products which are useful in early diagnosis, prognosis and theranostic use of Alzheimer’s disease.

By entering this agreement, IBL expects great synergistic effects of collaborative R&D work with ADx in Alzheimer’s disease which will accelerate the development of novel in-vitro diagnostic (IVD) products use in the field, worldwide.

About ADx

ADx NeuroSciences is a new biotech company focused on the development of (i) novel (bio)markers for use in dementia diagnosis (Dx) (Alzheimer’s (AD), Parkinson’s and other neurodegenerative diseases) and (ii) companion diagnostics. ADx NeuroSciences builds on its leading expertise, development know-how and capabilities to offer innovative solutions - from concept to clinical value - for Pharma and IVD.

http://www.adxneurosciences.com/

About IBL

IBL has been working on research and development of various antibodies which are recognized as fundamental research tools in biological technology filed since IBL was established in 1982. IBL has especially strong advantageous skills and know how in particular fields such as cancer, cerebral nerve related diseases, diabetes, fat metabolism related diseases and IBL has a broad range of RUO product lineup such as antibodies and ELISA kits used in these research field. IBL also provides a high quality of customized services for producing of antibodies. Thus IBL pursues development of antibodies and aim to develop its business into diagnostic and medical field. For additional information, please visit http://www.ibl-japan.co.jp/eng/index.htm
For further information contact:

Immuno Biological Laboratories Co., Ltd.

Dr. Noriaki Kinoshita

Director of Business Administration and the Head of

Department of Manufacturing and Product Development

Tel: +81-274-22-2889 Fax: +81-274-23-605